At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
In Brief
A Phase 2 clinical trial evaluating Eloralintide and Placebo for Obesity and Overweight. Completed, enrolled 263 participants across 43 sites.
Signals
Detailed Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits.
Study Details
Timeline
Arms & Interventions
Participants received subcutaneous (SC) injections of eloralintide-matching placebo administered once weekly (QW) for 48 weeks.
Participants received eloralintide 1 milligram (mg) SC QW for 48 weeks.
Participants received eloralintide 3 mg SC QW for 48 weeks.
Participants received eloralintide 6 mg SC QW for 48 weeks.
Participants received eloralintide 9 mg SC QW for 48 weeks.
Participants received eloralintide 6 mg SC QW for 20 weeks, followed by eloralintide 9 mg SC QW for 28 weeks, for a total treatment duration of 48 weeks.
Participants received eloralintide 3 mg SC QW for 4 weeks, followed by eloralintide 6 mg SC QW for 4 weeks, followed by eloralintide 9 mg SC QW for 40 weeks, for a total treatment duration of 48 weeks.
Interventions
Administered SC.
Administered SC.